Immunic begins phase II trial of COVID-19 immunotherapy

By The Science Advisory Board staff writers

July 27, 2020 -- Immunic has enrolled the first patients in a phase II clinical trial of Imu-838, a selective oral dihydroorotate dehydrogenase (DHODH) inhibitor, in combination with the neuraminidase inhibitor oseltamivir (Tamiflu).

The prospective, randomized, parallel-group, open-label phase IIb study will evaluate the safety of Imu-838 in approximately 120 adult patients with moderate to severe COVID-19 symptoms at University Hospitals Coventry and Warwickshire National Health Service Trust in the U.K. The company believes that there is a synergistic effect between direct antiviral drugs such as oseltamivir and DHODH inhibitors.

In preclinical studies Imu-838 has been shown to inhibit replication of SARS-CoV-2 with an attractive pharmacokinetic safety and tolerability profile. To date, the drug has been tested in around 650 individuals.

Imu-838 is also undergoing phase II trials in patients with COVID-19, ulcerative colitis, and relapsing-remitting multiple sclerosis, where top-line data is expected in the first half of August 2020.

Immunic begins phase II immunotherapy for COVID-19
Immunic has enrolled the first COVID-19 patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase (DHODH) inhibitor.

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter